PRTC News and Press, PureTech Health plc From 08/11/21

Imbrium Therapeutics has paid PureTech $6.5 million and PureTech is eligible to receive up to $53 million in additional development milestone payments for this program in addition to royalties on product sales Imbrium is responsible for all future development activities and fu...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") plans to announce its half-yearly results for the six months ended June 30, 2021, on Tuesday, August 24, 2021. A presentation and conference call for analysts will take place at 9:00am EDT / 2:00pm BST o...

New EndeavorRx ® features released as Akili begins to scale its commercial activities PureTech Health plc (Nasdaq:PRTC, LSE:PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, today announced that its Fo...

Proceeds expected to be used primarily to support a Phase 3 trial of Vedanta’s lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD) Topline data from Phase 2 trial of VE303 in CDI are anticipat...

Public listing of Gelesis, along with Karuna Therapeutics (Nasdaq: KRTX) and Vor Biopharma (Nasdaq: VOR), five other private Founded Entities and advanced Wholly Owned Pipeline, further exemplifies the success of PureTech’s unique value-generating model for developing new medic...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Vor Biopharma (Nasdaq: VOR) (“Vor”), announced the formation of a collaboratio...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, is pleased to note that its Founded Entity, Sonde Health (“Sonde”), today announced that it will collaborate with leading ...

Study will investigate potential activity of a novel immunotherapeutic (LYT-200) with checkpoint inhibition as a new treatment modality Topline Phase 1 results with single-agent LYT-200 expected in the fourth quarter of 2021 PureTech Health plc (Nasdaq: PRTC, LSE...

The new data were presented at the International Human Microbiome Consortium Congress 2021 Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative coliti...

Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences , a leading clinical-stage ...